Improving outcomes in pancreatic cancer: Key points in perioperative management

Table 1 Methods data of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma n (%)

	Year	n	Type study	Mean age (yr)	ChemotherapyAgents regimen			RadiotherapyDose (Gy) IORT
Gillen et al[2]	80-09	111	78P-33R	62.5	107 (96.4)	5FU > GEM > Tax > Others	44S + 48C	104 (93.7)	24-63	13 (12.5)
Assifi et al[35]	93-10	14	14P-0R	N/P	14 (100)	GEM > 5FU	3S + 11C	12 (85)	30-50	0 (0)
Andriulli et al[36]	97-08	20	20P-0R	63.0	20 (100)	GEM > Cis	13S + 7C	17 (85)	30-40	N/P

P: Prospective; R: Retrospective; 5FU: 5-fluor-uracil; GEM: Gemcitabine; Cis: Cisplatine; Tax: Taxanes; S: Single; C: Combined; IORT: Intraoperative radiotherapy; N/P: Not provided.

Table 2 Results of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma in terms of safety (postoperative morbidity and toxicity) and efficacy (response and resection)

		Response (%)			Resection (%)
	Toxicity (%)	Complete	Partial	Progression	Resected	R0	Mono	Combined	Postoperative morbidity (%)
Gillen et al[2]	01:26.3	3.6	30.6	20.9	73.6	60.4	80.9	66.2	26.7
	02:31.3	4.8	30.2	20.8	33.2	26.2	27.3	33.0	39.1
Assifi et al[35]	1:37	0.8	9.5	17.0	65.8	55.9	N/P	N/P	N/P
	02:46.2	4.0	31.8	21.8	31.6	19.6			N/P
Andriulli et al[36]	1:29	12		15.0	81.2	66.4	N/P	N/P	N/P
	2:33	27		32.0	26.4	16.0			N/P

1: Group of patients with potentially resectable pancreatic adenocarcinoma; 2: Group of patients with borderline resectable pancreatic adenocarcinoma. Toxicity: Only grade 3 and 4; Resection R0: Complete resection of the tumor; Resection Mono: Single chemotherapy drug; Resection Combined: Combined chemotherapy drugs; N/P: Not provided.

Table 3 Results of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma in terms of survival and mortality

	Mean Survival	Mortality	Estimated survival (%)
	(mo)	(%)	1-yr	2-yr
Gillen et al[2]	01:23.3	3.9	77.9	47.4
	02:20.5	7.1	79.8	50.1
Assifi et al[35]	01:15.1	N/P	N/P	N/P
	02:11.2
Andriulli et al[36]	01:18.8	N/P	91.7	86.3
	2:14		67.2	54.2

Referred only after surgical resection. 1: Group of patients with potentially resectable pancreatic adenocarcinoma; 2: Group of patients with borderline resectable pancreatic adenocarcinoma. N/P: Not provided.